If You Think Approval Is Hard, Try Selling A New Antibiotic
Executive Summary
Getting approval of a new antibiotic is just the first hurdle. Launching an anti-infective in the hospital setting is particularly challenging for sponsors pressured by both the requirements of antibiotic stewardship and an especially challenging reimbursement climate, as Theravance learned with Vibativ.
You may also be interested in...
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
Theravance Re-Introduces Vibativ In The U.S. Independently (For Now)
The biotech is bringing is long-plagued antibiotic back to U.S. patients, but is still searching for another company to help with commercialization efforts. Meanwhile, plans for its split and the launch of its partnered COPD drug are on track.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.